The pursuit and development of clinically relevant biomarkers has also fueled growth of the companion diagnostics industry—a notable example being the CD340 biomarker used to identify patients for trastuzumab (Herceptin®), the first in class Dx/Rx combination for treatment of HER2-positive breast cancers [9]. This evidence concerns the gene ERBB2 and breast cancer.